Emerging Markets And Global Aging Will Elevate Biosimilars
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
20 Aug 25
Updated
20 Aug 25
AnalystHighTarget's Fair Value
US$14.00
23.9% undervalued intrinsic discount20 Aug
US$10.65
1Y
-9.1%7D
2.3%